Saturday, May 18, 2024
Home » LUPIN LAUNCHES RUFINAMIDE ORAL SUSPENSIONS IN THE US

LUPIN LAUNCHES RUFINAMIDE ORAL SUSPENSIONS IN THE US

by Koushik Gope
0 comment

Lupin Pharmaceuticals, Inc., a global pharmaceutical company, announced the launch of Rufinamide oral suspensions in the United States. Rufinamide is a prescription medication used to treat seizures associated with Lennox-Gastaut syndrome (LGS) in adults and children ages 1 year and older.

Rufinamide is available in two strengths: 200 mg/mL and 400 mg/mL. The suspensions are grape-flavored and can be taken with or without food.

The launch of Rufinamide oral suspensions is a significant milestone for Lupin. The company has been working on the development of the product for several years, and it is the first and only oral suspension of rufinamide available in the US.

Rufinamide is a well-established treatment for LGS. It is a centrally acting anticonvulsant that works by stabilizing neuronal membranes. The drug is generally well-tolerated, and the most common side effects are somnolence, dizziness, and headache.

The launch of Rufinamide oral suspensions is expected to make the drug more accessible to patients with LGS. The suspensions are easier to administer than capsules, and they are also more palatable for children.

Lupin is a leading provider of generic and specialty pharmaceuticals in the US. The company has a strong track record in developing and launching innovative products, and the launch of Rufinamide oral suspensions is a testament to its commitment to providing patients with access to high-quality medications.

Here are some of the benefits of Rufinamide oral suspensions:

  • Easy to administer: The suspensions are easy to measure and administer, making them a good option for children and adults who have difficulty swallowing capsules.
  • Palatable: The grape-flavored suspensions are palatable for most patients, making them more likely to take the medication as prescribed.
  • More accessible: The suspensions are available in a wider range of doses than the capsules, making them more accessible to patients with different needs.

Conclusion

The launch of Rufinamide oral suspensions is a significant milestone for Lupin and for patients with LGS. The suspensions are a more convenient and palatable way to take rufinamide, and they are expected to make the drug more accessible to patients.thumb_upthumb_downuploadmore_vert

You may also like

Leave a Comment

Welcome to the world of ISMDU, here we help you stay up-to-date on the latest market trends and news from around the world. Our mission is simple: to educate our readers about what’s happening in the stock market, so they can be prepared when opportunities arise.

© 2023 ISMDU • Designed by Dimagital Media